Indeed, promoter hypermethylation of TMEM88 is associated with poorer prognosis of non-small cell lung cancer (Ma et al., 2017), whereas the hypomethylation is associated with platinum resistance in ovarian cancer (de Leon et al., 2016). Here, TMEM88 is linked to non-small cell lung carcinoma.